今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

高尔宣北美巡演多伦多站官宣：9月1日登陆多伦多Pavilion，唱响青春热血！

多伦多，2023年6月1日 – 备受瞩目的华语新星OSN高尔宣今日宣布，他将于2023年9月1日在多伦多Pavilion举行北美巡演多伦多站的演唱会。此次巡演将是高尔宣继英国巡演之后首次踏上北美舞台，也是他向国际舞台迈出的重要一步。

高尔宣凭借其独特的Rap音乐风格和魅力迅速赢得了全球粉丝的喜爱，专辑《#OSNRAP》在油管上累计播放超过2.2亿，其中单曲《Without You》更是播放超过8400万。他的音乐融合了说唱和现代流行元素，充满活力和创造力，在亚洲取得巨大成功，也引起了国际舞台的广泛关注。

多伦多站演唱会将由PINK Entertainment主办，届时高尔宣将带来他的众多热门单曲，包括《Without You》、《Drive》、《Can't Let You Go》、《Remember Me》等，并与特邀嘉宾一起为观众献上精彩的演出。

主办方表示：“我们很高兴将高尔宣带到多伦多，相信他的音乐将吸引所有热爱音乐的粉丝。这场演唱会不仅是高尔宣北美巡演的重要一站，也是华语流行音乐走向国际舞台的一次重要展示。”

高尔宣北美巡演多伦多站门票将于近期开售，更多信息敬请留意官方售票渠道。

关于高尔宣

OSN高尔宣，本名高嘉朗，是一位来自马来西亚的华裔歌手。2019年，他凭借一首《Without You》迅速走红，并陆续发行多首热门单曲，包括《Drive》、《Can't Let You Go》、《Remember Me》等。他的音乐风格融合了说唱和现代流行元素，充满活力和创造力，深受年轻人的喜爱。高尔宣曾多次获得音乐奖项，并登上多档热门综艺节目。2023年，他将开启北美巡演，将他的音乐带到更多世界各地的歌迷面前。

延伸阅读

• OSN高尔宣北美巡演官宣 多伦多站9月1日开唱 https://portal.sina.com.hk/entertainment/sina/2023/06/01/369277/osn%E9%AB%98%E7%88%BE%E5%AE%A3%E5%8C%97%E7%BE%8E%E5%B7%A1%E6%BC%94%E5%A4%9A%E5%80%AB%E5%A4%9A%E7%AB%99%E5%AE%98%E5%AE%A3-9%E6%9C%881%E6%97%A5%E5%B0%87%E9%96%8B%E5%94%B1/
• OSN高尔宣北美巡演多伦多站：华语流行乐走向国际舞台 https://c.m.163.com/news/hot/newsList